George Cardoza
George Cardoza's purchase track record
George Cardoza has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/5/2026 | SOPH | $99K | +61.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
Transaction History
| SOPH | ▼ Sell | Open Market | 1,592 | $8K | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 774 | $4K | 6/22/2026 | View on chart |
| SOPH | ▲ Buy | Open Market | 20,000 | $99K | 6/5/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 1,403 | $7K | 4/8/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,413 | $12K | 4/7/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,520 | $12K | 4/6/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 112,936 | $0 | 4/2/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 774 | $4K | 3/19/2026 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 839 | $0 | 3/2/2022 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 503 | $0 | 3/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 61,143 | $0 | 12/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum
Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.